Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 1/20 | 0.41 |
| ▸ | CDK9 | P50750 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 5/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6418077 | 0.89 | MAPT (0.45) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6416052 | 0.88 | MAPT (0.40) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6418080 | 0.88 | MAPT (0.40) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6417508 | 0.87 | BRD4 (0.39) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6417474 | 0.86 | MAPT (0.39) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6417674 | 0.86 | MAPT (0.39) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6416100 | 0.86 | MAPT (0.39) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6416980 | 0.85 | MAPT (0.39) | CCNT1CDK9DRD2MAPTPOLB | |
| SCHEMBL6419051 | 0.84 | MAPT (0.39) | DRD2MAPTPOLBGAATP53 | |
| SCHEMBL6421163 | 0.83 | MAPT (0.45) | CCNT1CDK9DRD2MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | BAYER HEALTHCARE AG (DE) | 2005-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119489-A1 | 4-Sulfide/sulfoxide/sulfonyl-1h-pyrazolyl derivative compounds, for use in diseases associated with the 5-ht2c receptor | HTR2C, HTR2A, HTR2B | CCNT1 2260/4885CDK9 2329/4885DRD2 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.